PDC*line Pharma
PrivateLast Round
Grant
Jan 17, 2024
Total Funding Raised
$26.98M
Company Overview
PDC*line Pharma is a biotechnology company that develops a class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PDC*line Pharma Comparables
Compare PDC*line Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OxVax Ltd. | 84% | |
| IO Biotech | 78% | |
| Mendus AB | 76% | |
PDC*line Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 17, 2024 | ||||
| Series B Extension | Dec 6, 2021 | ||||
| Debt | Jan 22, 2020 | ||||
| Debt | Dec 6, 2016 |
PDC*line Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Debt, Series B Extension |
| Korea Investment Partners | Debt, Series B Extension |
| Noshaq | Debt, Series B Extension |
| Société Régionale d'Investissement de Wallonie | Debt, Series B Extension |
| Wallonie Entreprendre | Grant |
| Brain Asset Management Co.,Ltd. | Series B Extension |
| Korea Investment Partners | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 17, 2024
$5.1M grant received from BioWin and government entities.
- Dec 6, 2021
$14M round led by Korea Investment Partners.
PDC*line Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PDC*line Pharma's valuation, stock price, and market status.